193 related articles for article (PubMed ID: 10399506)
41. Clinical potential of antithrombotic drugs in coronary syndromes.
Turpie AG
Am J Cardiol; 1998 Sep; 82(5B):11L-14L. PubMed ID: 9737474
[TBL] [Abstract][Full Text] [Related]
42. The role of low-molecular-weight heparins in cardiovascular medicine.
Hödl R; Klein W
J Clin Pharm Ther; 2003 Oct; 28(5):371-8. PubMed ID: 14632961
[TBL] [Abstract][Full Text] [Related]
43. Antithrombotic therapy in acute coronary syndromes: key notes from ESSENCE and TIMI 11B.
Fox KA
Semin Hematol; 2001 Apr; 38(2 Suppl 5):67-74. PubMed ID: 11449345
[TBL] [Abstract][Full Text] [Related]
44. [Low molecular weight heparin in unstable angina].
Kher A; Samama MM
Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1495-500. PubMed ID: 9092409
[TBL] [Abstract][Full Text] [Related]
45. Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature.
Rubboli A; Ottani F; Capecchi A; Brancaleoni R; Galvani M; Swahn E
Cardiology; 2007; 107(2):132-9. PubMed ID: 16864962
[TBL] [Abstract][Full Text] [Related]
46. Patterns of use of heparins in ACS. Correlates and hospital outcomes: the Global Registry of Acute Coronary Events (GRACE).
Klein W; Kraxner W; Hödl R; Steg PG; Budaj A; Gulba D; Sadiq I; van de Werf F; White K; Fox KA;
Thromb Haemost; 2003 Sep; 90(3):519-27. PubMed ID: 12958622
[TBL] [Abstract][Full Text] [Related]
47. Reduction of myocardial damage by prolonged treatment with subcutaneous low molecular weight heparin in unstable coronary artery disease. FRISC study group. Fragmin during Instability in Coronary Artery Disease.
Sätre H; Holmvang L; Wagner GS; Lindahl B; Wallentin L
Eur Heart J; 1999 May; 20(9):645-52. PubMed ID: 10208784
[TBL] [Abstract][Full Text] [Related]
48. The role of low-molecular-weight heparins in the management of unstable angina and non-ST elevation myocardial infarction.
Alwi I
Acta Med Indones; 2008 Oct; 40(4):228-32. PubMed ID: 19530369
[TBL] [Abstract][Full Text] [Related]
49. [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
Husted SE; Nielsen HK
Ugeskr Laeger; 2010 Oct; 172(42):2888-91. PubMed ID: 21040659
[TBL] [Abstract][Full Text] [Related]
50. [Low-molecular-weight heparins in unstable angina and non-Q-wave myocardial infarction].
Rubio-Terrés C; Pajuelo F; Margalet I
Med Clin (Barc); 2001 May; 116(16):638-9. PubMed ID: 11412657
[No Abstract] [Full Text] [Related]
51. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.
Montalescot G; Collet JP; Lison L; Choussat R; Ankri A; Vicaut E; Perlemuter K; Philippe F; Drobinski G; Thomas D
J Am Coll Cardiol; 2000 Jul; 36(1):110-4. PubMed ID: 10898421
[TBL] [Abstract][Full Text] [Related]
52. Low molecular weight heparins better than unfractionated heparin in unstable coronary artery disease? Unstable angina pectoris/non-Q wave infarction a partly outpatient clinic condition?
Kauw FH; Cleophas TJ; Kalmansohn RB
Int J Clin Pharmacol Ther; 1998 Jul; 36(7):392-7. PubMed ID: 9707355
[TBL] [Abstract][Full Text] [Related]
53. New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials.
Cohen M
Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S343-52. PubMed ID: 9628448
[TBL] [Abstract][Full Text] [Related]
54. Low-molecular-weight heparins and glycoprotein IIb/IIIa antagonists in acute coronary syndromes.
Ferguson J
J Invasive Cardiol; 2004 Mar; 16(3):136-44. PubMed ID: 15152164
[TBL] [Abstract][Full Text] [Related]
55. Antithrombotic drugs for older subjects. Guidelines formulated jointly by the Italian Societies of Haemostasis and Thrombosis (SISET) and of Gerontology and Geriatrics (SIGG).
Di Minno G; Tufano A; Cerbone AM
Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):41-62. PubMed ID: 11383324
[TBL] [Abstract][Full Text] [Related]
56. Assessment of low-molecular-weight heparin trials in cardiology.
Shulman RI
Pharmacol Ther; 2000 Jul; 87(1):1-9. PubMed ID: 10924738
[TBL] [Abstract][Full Text] [Related]
57. Defining the scope of evidence-based practice for low-molecular-weight heparin therapy in high-risk patients with unstable angina and non-ST-elevation myocardial infarction.
Ferguson JJ
Clin Cardiol; 2002 Nov; 25(11 Suppl 1):I16-22. PubMed ID: 12428815
[TBL] [Abstract][Full Text] [Related]
58. Present treatment options for unstable angina and non-Q-wave myocardial infarction.
Lairikyengbam SK; Davies AG; Anderson MH
QJM; 2001 Jan; 94(1):5-11. PubMed ID: 11161130
[No Abstract] [Full Text] [Related]
59. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
Haas S
Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
[TBL] [Abstract][Full Text] [Related]
60. Current roles and future possibilities for low-molecular-weight heparins in unstable angina.
Purcell H; Fox KM
Eur Heart J; 1998 Sep; 19 Suppl K():K18-23. PubMed ID: 9790285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
